EGFR-directed antibodies increase the risk of severe infection in cancer patients

BMC Medicine

Barbara Burtness¹  Mehmet Altan¹ 

[1] Yale University School of Medicine and Yale Cancer Center, 333 Cedar Street, WWW225, New Haven 06520-8028, CT, USA

关键词: Monoclonal antibody;    Infection;    EGFR;   

Others  :  1130612
DOI  :  10.1186/s12916-015-0276-9

 received in 2015-01-14, accepted in 2015-01-15,  发布年份 2015

【 摘 要 】

Monoclonal antibodies directed to the epidermal growth factor receptor (EGFR) have a role in the management of several solid tumors, alone or in combination with chemotherapy or radiation therapy. Recognized toxicities have included hypersensitivity reactions, rash, hypomagnesemia, and constitutional symptoms, but the possibility that the agents lead to immunosuppression or increase the risk of infection has only recently been recognized. Two latest meta-analyses, including the recently published article by Qi et al., highlight the increased risk of severe infections with EGFR-directed monoclonal antibodies. Further studies are needed to better identify the association between EGFR-directed monoclonal antibody treatment and infection, as well as to elucidate the mechanism of this toxicity and to develop tools to identify patients at increased risk for these complications. In the meantime, awareness of the role of EGFR-directed antibodies in increased infection risk may have implications for dose modification strategies in both clinical trial design and the practice of oncology.

Please see related article: http://www.biomedcentral.com/1741-7015/12/203 webcite.

【 授权许可】

   
2015 Altan and Burtness; licensee BioMed Central.

【 参考文献 】

• [1]Arteaga CL, Engelman JA: ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014, 25:282-303.
• [2]Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005, 23:8646-8654.
• [3]Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354:567-578.
• [4]Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359:1116-1127.
• [5]Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al.: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012, 48:1466-1475.
• [6]Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al.: Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014, 15:569-579.
• [7]Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22:1201-1208.
• [8]Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al.: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008, 358:1109-1117.
• [9]Qi WX, Fu S, Zhang Q, Guo XM: Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med. 2014, 12:203. BioMed Central Full Text
• [10]Funakoshi T, Suzuki M, Tamura K: Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. Canc Treat Rev 2014, 40:1221-1229.
• [11]Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, et al.: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011, 12:333-343.
• [12]Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, et al.: An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014, 73:1227-1239.
• [13]Funakoshi T, Suzuki M, Muss HB: Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis. Breast Canc Res Treat 2015, 149:321-330.
• [14]Chattopadhyay S, Sen GC: Tyrosine phosphorylation in Toll-like receptor signaling. Cytokine Growth Factor Rev 2014, 25:533-541.
• [15]Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal growth factor receptor is essential for toll-like receptor 3 signaling”. Science Signaling. 2012;5(254):lc5.